Compositions and methods using combinations of nutrients to support cognitive and emotional health in mammals
A synergistic combination of nutrients like spermidine and ellagic acid, or DHA and curcumin, addresses cognitive and emotional health issues in aging mammals by enhancing cognitive function and emotional well-being without lifestyle changes, improving quality of life.
Patent Information
- Application Number
- JP2024516920
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-04
- Filing Date
- 2022-10-27
- Publication Date
- 2024-11-19
AI Technical Summary
Aging mammals, including humans and companion animals, often suffer from cognitive impairment and emotional health issues such as anxiety, aggression, and dementia, which are not effectively addressed by existing lifestyle changes like caloric restriction or single nutrient supplementation, and require more efficient nutritional solutions.
A synergistic combination of nutrients, such as spermidine and ellagic acid, or docosahexaenoic acid (DHA) and curcumin, is administered to support cognitive and emotional health without requiring lifestyle changes, acting as 'caloric restriction mimetics' to enhance cognitive function and emotional well-being.
The nutrient combinations effectively improve cognitive function, reduce anxiety and depression, and enhance emotional health, improving the quality of life for both individuals and their pets by supporting mental stability, memory, and social behavior.
Smart Images

Figure 2024542922000001 
Figure 2024542922000002 
Figure 2024542922000003
Abstract
Description
[Background technology]
[0001]
[0001] The present disclosure generally relates to mammalian nutrition and its effects on cognitive function, behavior, and brain physiology, as well as emotional health. In particular, the present disclosure utilizes nutrient combinations, such as spermidine and ellagic acid, and / or docosahexaenoic acid (DHA) and curcumin, to support cognition in aging or elderly mammals, such as humans or companion animals, as well as the emotional regulation of the mammal's thoughts, feelings, and behaviors.
[0002] Aged or elderly animals often suffer from some degree of cognitive impairment. Age-related changes, including progressive cognitive decline, as well as age-related changes in brain morphology and cerebrovascular function, such as brain aging, are commonly observed. Age-related or age-associated cognitive impairments may manifest in many ways, particularly in the form of short-term memory impairment, reduced learning ability, reduced learning speed, reduced attention, reduced motor skills, and / or dementia. In some cases, the exact etiology of these cognitive declines is unclear. In other cases, cognitive impairments result from the onset or progression of recognized diseases, disorders, or syndromes, such as Alzheimer's disease (AD). It is known that age-related cognitive decline can be distinct from AD and can occur independently of AD.
[0003]
[0003] Animal models of cognitive disorders are a powerful aid in the study of such conditions, including physiology, neurology, anatomy, and pathology. Dogs are a useful model animal that show age-related cognitive decline in learning and memory that varies depending on the role of the cognitive task (Adams B et al., 2000a; Chan ADF et al., 2002; Su MY et al., 1998; and Tapp PD et al., 2003). While the study of such decline in dogs is useful in itself because of their role as companion animals, the fact that the observed decline resembles the age-related cognitive decline seen in humans (Adams B et al. 2000b) makes this study even more useful. Aging dogs develop neuropathology related to beta-amyloid protein and other proteins seen in both normal aging humans and AD patients (Cotman CW and Berchtold, 2002; and Cummings BJ et al., 1996). However, dogs do not display all the features of AD, in particular tau-containing neurofibrillary tangles (Dimakopoulos AC et al., 2002), and therefore the condition in dogs is distinct and is referred to as Canine Cognitive Dysfunction Syndrome (CCDS).
[0004]
[0004] Both healthy and unhealthy dogs (e.g., dogs diagnosed with CCDS) may clinically have progressive cognitive impairment and neuropathological changes (London ED et al., 1983). In addition, older dogs and dogs diagnosed with CCDS show various behavioral disorders. For example, diagnosed dogs may not respond to their name or familiar commands, become lost or confused even in familiar places, not greet or respond to owners or visitors, show reduced daytime activity, walk in circles, avoid affection, and lose bladder or bowel control.
[0005]
[0005] Senior companion animals are the fastest growing segment of the pet population. Importantly, senior pets experience behavioral changes such as anxiety, aggression, and cognitive impairments that are associated with brain damage. These compounding behavioral changes have a measurable and perceptible impact on the emotional well-being of pets and their owners. Summary of the Invention
[0006]
[0006] Dietary modification is a powerful intervention to delay and slow the progression of many age-related diseases, such as brain-related disorders, and consumers are increasingly becoming aware of this concept. The most effective and scientifically validated interventions that are beneficial during aging are based on either calorie restriction, dietary regimens that reduce food intake without leading to malnutrition, or the implementation of fasting regimens.
[0007]
[0007] However, calorie restriction and fasting involve significant nutritional and behavioral constraints, leading to low compliance with such dietary protocols or resistance to such dramatic lifestyle changes in most people. These challenges also apply to pets.
[0008]
[0008] Furthermore, existing data on improving mental and cognitive health by activating autophagy currently focuses on lifestyle changes such as calorie restriction, intermittent fasting, or long-term exercise. The above lifestyles are not easy to adhere to, especially for middle-aged and senior people, so this solution is not effective for almost everyone in this population. At the same time, supplementation with a single nutrient may require high doses or may be less effective, and more effective combinations need to be found.
[0009]
[0009] Therefore, the inventors attempted to find nutritional solutions or nutrients that act as "caloric restriction mimetics (CRMs)". CRMs are defined as ingredients that simulate the health-promoting effects of fasting without the need for lifestyle changes. A list of known and putative CRMs in animal models and humans has recently been published in Madeo at al. Cell Metab. 20191.
[0010]
[0010] The present disclosure leverages the highly validated science associated with CRM to reveal nutritional solutions that, first, support cognitive performance and mood (cognition, anxiety, social behavior) during aging, and second, significantly improve the quality of life of senior pets, e.g., senior dogs aged 7 years and older, and indirectly the quality of life of their owners.
[0011]
[0011] Complementing the behavioral benefits, a "biomarker signature" of the blend has been shown in rodent studies. Biomarkers include delayed biological aging as measured by blood glucose / insulin metabolism, blood oxidative stress markers (e.g., C-reactive protein), and epigenetics, as well as inflammatory markers. Non-invasive biomarkers can be used in further canine studies and to inform veterinary practices.
[0012]
[0012] As described herein, the inventors found synergistic activation of transcription factor EB (TFEB) downstream genes involved in lysosomal biogenesis with similar effect size to other solutions reported in the literature, which should increase efficacy in supporting cognitive and emotional health simultaneously.
[0013]
[0013] Compared to single ingredient supplementation, the present disclosure provides a more efficient and synergistic blend of nutrients to support cognitive and emotional health (e.g., anxiety, mood and despair), bridging the gap between lifestyle changes and effective nutritional solutions to support cognitive and emotional states in adult and senior pets and humans.
[0014]
[0014] Thus, in a general embodiment, the disclosure provides a composition comprising a combination of nutrients for enhancing cognitive function and emotional health. The disclosure also provides a method comprising administering one of these compositions in an amount effective to enhance cognitive function and emotional health. Enhancement of cognitive function and emotional health can include (a) preventing, reducing, delaying and / or treating at least one of cognitive impairment, neurodegenerative conditions, stroke, dementia, or age-related cognitive decline; (b) reducing at least one of anxiety, depression, negative affect, stress, aggression, hopelessness, lack of concentration, or irritability; and / or (c) maintaining or improving at least one of mood, happiness, positive affect, mental well-being, or social behavior (e.g., reducing impulsive behavior).
[0015]
[0015] The composition is administered to a mammal (e.g., a mammal in need of enhanced cognitive and emotional health), preferably a companion animal or a human, e.g., a senior companion animal, a geriatric companion animal, a senior human or an elderly human.
[0016] In some embodiments, the nutrient combination comprises a combination of spermidine and ellagic acid. In some embodiments, the nutrient combination comprises a combination of docosahexaenoic acid (DHA) and curcumin.
[0017] An advantage of one or more embodiments provided by the present disclosure are compositions and methods for improving cognitive and emotional health, particularly in companion animals or humans, such as elderly companion animals or elderly humans.
[0018] Another advantage of one or more embodiments provided by the present disclosure are compositions and methods for the treatment and / or prevention of cognitive disorders, neurodegenerative conditions, stroke, and dementia.
[0019] Yet another advantage of one or more embodiments provided by the present disclosure is that it improves the overall quality of life for both pets and pet owners.
[0020] A further advantage of the present disclosure is that it improves not only the lifespan but also the quality of life of individuals and their pets.
[0021]
[0021] Additional features and advantages are described in, and will be apparent from, the following detailed description and drawings. [Brief description of the drawings]
[0022] [Figure 1A] In the experimental examples disclosed herein, the results obtained with the combination of DHA and curcumin with respect to autophagy-related genes are shown. [Figure 1B] In the experimental examples disclosed herein, the results obtained with the combination of DHA and curcumin with respect to autophagy-related genes are shown. [Figure 2A] In the experimental examples disclosed herein, the results obtained with the combination of DHA and curcumin on lysosome-related genes are shown. [Figure 2B] In the experimental examples disclosed herein, the results obtained with the combination of DHA and curcumin on lysosome-related genes are shown. [Figure 3A] In the experimental examples disclosed herein, the results obtained with respect to autophagy-related genes by the combination of spermidine and ellagic acid are shown. [Figure 3B] In the experimental examples disclosed herein, the results obtained with respect to autophagy-related genes by the combination of spermidine and ellagic acid are shown. [Figure 4A] In the experimental examples disclosed herein, the results obtained with a combination of spermidine and ellagic acid on lysosome-related genes are shown. [Figure 4B] In the experimental examples disclosed herein, the results obtained with a combination of spermidine and ellagic acid on lysosome-related genes are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023]
[0026] definition
[0027] Some definitions are provided below. However, definitions may be found in the "Embodiments" section below, and the heading "Definitions" above does not imply that such disclosure in the "Embodiments" section is not a definition.
[0024]
[0028] All percentages are by weight relative to the total weight of the composition unless otherwise stated.Similarly, all ratios are by weight unless otherwise stated.When reference is made to pH, the value corresponds to the pH measured at 25°C by standard equipment.As used herein, "about", "approximately" and "substantially" are understood to refer to a number within a certain range of numerical values, for example, within the range of -10% to +10% of the reference number, preferably within the range of -5% to +5% of the reference number, more preferably within the range of -1% to +1% of the reference number, and most preferably within the range of -0.1% to +0.1% of the reference number.
[0025]
[0029] Moreover, all numerical ranges herein should be understood to include all integers, whole or fractional, within that range. Moreover, these numerical ranges should be interpreted to support claims directed to any number or subset of numbers within that range. For example, a disclosure of 1 to 10 should be interpreted to correspond to ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.
[0026]
[0030] As used in this specification and the appended claims, singular words include the plural unless the context clearly indicates otherwise. Thus, references to "a," "an," and "the" generally include the plural of the respective terms. For example, a reference to "an ingredient" or "a method" includes a plurality of such "ingredients" or "methods." The term "and / or" used in the context of "X and / or Y" should be interpreted as "X" or "Y" or "X and Y." Similarly, "at least one of X or Y" should be interpreted as "X" or "Y" or "both X and Y."
[0027]
[0031] Similarly, the terms "comprise," "comprises," and "comprising" should be interpreted as inclusive rather than exclusive. Similarly, the terms "include," "including," and "or" should all be interpreted as inclusive unless such interpretation is clearly prevented by the context. However, embodiments provided by the present disclosure may not include any element not specifically disclosed herein. Thus, disclosure of an embodiment defined using the term "comprising" is also a disclosure of an embodiment "consisting essentially of," and "consisting of," the identified components.
[0028]
[0032] As used herein, the term "example," particularly when followed by a list of terms, is merely exemplary and illustrative and should not be considered as exclusive or comprehensive. All embodiments disclosed herein can be combined with any other embodiment disclosed herein, unless expressly stated otherwise.
[0029]
[0033] "Animal" includes, but is not limited to, rodents, aquatic mammals, domestic animals such as dogs and cats, livestock such as sheep, pigs, cows and horses, and mammals including, but not limited to, humans. When "animal", "mammal", or plurals thereof are used, these terms also apply to any animal capable of the effect indicated or intended to be indicated by the context of the text, for example, animals capable of autophagy. As used herein, the term "patient" is understood to include animals, for example, mammals, preferably humans, that are undergoing or will undergo treatment as defined herein. As used herein, the terms "individual" and "patient" are often used to refer to humans, but the present disclosure is not limited to humans.
[0030]
[0034] Thus, the terms "individual" and "patient" refer to any animal, mammal or human that may benefit from the methods and compositions disclosed herein. Indeed, non-human animals experience long-term and serious illnesses that mimic the human condition, and also experience the effects of aging.
[0031]
[0035] The term "elderly" in the human context means an age of at least 55 years, preferably greater than 63 years, more preferably greater than 65 years, and most preferably greater than 70 years. The term "older adult" or "ageing individual" in the human context means an age of at least 45 years, preferably greater than 50 years, and more preferably greater than 55 years, and includes geriatric individuals.
[0032]
[0036] For other animals, such as companion animals (i.e., cats or dogs), "middle-aged" or "elderly individuals" refer to animals that have exceeded 50% of the average lifespan of their respective species and / or genus within a species. An animal is considered "old" or "senior" if it has exceeded 66% of its average lifespan, preferably if it has exceeded 75% of its average lifespan, and more preferably if it has exceeded 80% of its average lifespan. An elderly cat or dog is at least about 5 years old. An elderly or senior cat or dog is at least about 7 years old.
[0033]
[0037] The term "cognitive function" refers to the special, normal, or appropriate physiological activity of the brain, including one or more of mental stability, memory / recall ability, problem-solving ability, reasoning ability, thinking ability, judgment ability, discrimination or selection ability, learning ability, learning ease, perception, intuition, attention, and cognition. "Enhancing cognitive function" or "improving cognitive function" refers to any improvement in the special, normal, or appropriate physiological activity of the brain, including one or more of mental stability, memory / recall ability, problem-solving ability, reasoning ability, thinking ability, judgment ability, discrimination or selection ability, learning ability, learning ease, perception, intuition, attention, and cognition, as measured by any means suitable in the art.
[0034]
[0038] Further in this regard, cognition is the mental process of learning and understanding through thought, experience, and the senses. Cognition includes perception; attention; the formation of knowledge, memory, judgments, and evaluations; reasoning, problem solving, and decision making; and language comprehension and production.
[0035]
[0039] As non-limiting examples, cognitive function can be assessed by a variety of cognitive tasks specific to each cognitive domain, although various embodiments of the compositions and methods disclosed herein are not limited to any particular test.
[0036]
[0040] For example, cognitive domains of executive function (e.g., concept formation, abstraction, set shifting, set maintenance, planning, self-monitoring, and allocation of attention) can be assessed by common neurocognitive tests such as the Wisconsin Card Sorting Test (WCST), Trail Making Test Part B (TMT B), Stroop Color Word Interference Test (SCWT), Category Test, Block Patterns (WAIS-R), Picture Completion (WAIS-R), Concept Shift Task (CST), Tower of London Task (TOL; CANTAB), Stockings of Cambridge (CANTAB), Intradimensional / Extradimensional Shift Test (CANTAB; IED), Spatial Span (SSP; CANTAB), Rough Figure Fluency Test (RFFT), Verbal Fluency - Letter Fluency and Semantic Category Fluency Test, Controlled Oral Word Association Test (COWAT), and the Delis-Kaplan Executive Function System (D-KEFS).
[0037]
[0041] As another example, the cognitive domains of attention and processing speed can be assessed by one or more common neurocognitive tests such as the Digit Sign Substitution Test (DSST; WAIS-R), Digit Span (Forward and Backward) (WAIS-R), Sustained Processing Task (CPT), Reaction Time (RTI; CANTAB), Choice Reaction Time (CRT; CANTAB), Simple Reaction Time (SRT; CANTAB), Trail Making Test Part A (TMT A), Speeded Auditory Serial Addition Test (PASAT), and Serial Subtraction of Sevens Test (SSST).
[0038]
[0042] As yet another example, the cognitive domain of working memory can be assessed by one or more common neurocognitive tests, such as arithmetic (WAIS-R), digit span (forward and backward) (WAIS-R), delayed recognition span test (DRST), spatial working memory (SWM; CANTAB), speech-phonetic ordering (LNS; WMS-R), logical memory (WMS-R), and an n-back task.
[0039]
[0043] For example, the cognitive domains of verbal learning and memory can be assessed by one or more common neurocognitive tests, such as the California Verbal Learning Test (CVLT), Rey Auditory Verbal Learning Test (RAVLT), Rivermead Behavioral Memory Test (RBMT), Hopkins Verbal Learning Test-Revised (HVLT-R), Logical Memory (WMS-R), Verbal Paired Associations (VPA; WMS-R), Visual Verbal Learning Test (VVLT), Digit Span (Forward and Reverse) (WAIS-R), Luria Verbal Learning Test (LVLT), Serial Seven Subtraction Test (SSST), and Verbal Recognition Memory Test (VRM; CANTAB).
[0040]
[0044] As another example, the cognitive domain of visual learning and memory can be assessed by one or more common neurocognitive tests, such as visual recall (WMS-R), Benton Visual Retention Test (VRT), Benton Visual Discrimination Test (VFD), Rey-Osterrieth Complex Figure Scale (ROCF), Kimura's Figure Recognition Task (RFT), Visual Verbal Learning Test (VVLT), Pattern Recognition Memory (PRM; CANTAB), Spatial Recognition Memory (SRM; CANTAB), Delayed Matching to Sample (DMS; CANTAB), Paired Associate Learning (PAL; CANTAB), and Matching Picture Finding Test 2 (MFFT-20).
[0041]
[0045] As yet another example, the cognitive domain of language and verbal comprehension can be assessed by one or more common neurocognitive tests, such as the Controlled Oral Word Association Test (COWAT), Verbal Fluency-Semantic Category Fluency and Letter Fluency, Similarities (WAIS-R), Words (WAIS-R), Knowledge (WAIS-R), Comprehension (WAIS-R), and Tokens Test.
[0042]
[0046] For example, the cognitive domain of visuospatial / perceptual processing can be assessed by one or more common neurocognitive tests, such as Judgement of Line Orientation (JOLO), Benton Visual Discrimination Test (VFD), Building Blocks Inventory (WAIS-R), and Visuospatial Span (Forward and Reverse) (WMS-R).
[0043]
[0047] As another example, the cognitive domains of brief mental status and general intelligence can be assessed by one or more common neurocognitive tests, such as the Mini-Mental State Examination (MMSE), Raven's Progressive Matrices, Wechsler Adult Intelligence Scale-Revised (WAIS-R), National Adult Reading Test (NART), Wechsler Adult Reading Assessment (WTAR), and Nonverbal Test of Intelligence-3 (TONI-3).
[0044]
[0048] As yet another example, the cognitive domain of the cognitive battery can be assessed by one or more common neurocognitive tests, such as the Cambridge Neuropsychological Test Automated Battery (CANTAB), Wechsler Memory Scale-Revised (WMS-R), Wechsler Adult Intelligence Scale-Revised (WAIS-R), Victoria Symptom Validity Test (VSVT), CalCAP (California Computerised Assessment Package), CNS Vital Signs, Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ), and the Delis-Kaplan Executive Function System (D-KEFS).
[0045]
[0049] For example, the cognitive domain of psychomotor function can be assessed by one or more common neurocognitive tests, such as finger tapping, the grooved pegboard test, and the Purdue Pegs.
[0046]
[0050] As another example, the cognitive domains of decision-making and response control can be assessed by one or more common neurocognitive tests, such as the Go / No-go Association Task (GNAT; CANTAB), the Information Gambling Task (IST; CANTAB), and the Cambridge Gambling Task.
[0047]
[0051] As another example, the cognitive domain of induction can be assessed by one or more common neurocognitive tests, such as the Big / Little Circle (BLC; CANTAB).
[0048]
[0052] As used herein, "emotional health" can be assessed, for example, by one or more of clinical interviews, behavior-symptom checklists, self-reported measures of personality, state, trait and behavior, and projective tests (e.g., drawings, sentence completion, stories, inkblots), or physiological markers related to emotional response and emotion regulation (e.g., autonomic nervous system-related markers such as heart rate, heart rate variability, respiration rate, skin conductance; structure, function or activation of mood-related, stress-related, or emotion regulation-related brain regions and networks, such as, for example, central nervous system-related: amygdala, hippocampus, prefrontal cortex, emotion regulation network; EEG and event-related potentials, such as those related to emotion recognition). The term "behavior" means anything an animal does in response or reaction to a given stimulus or set of conditions. "Enhanced behavior" or "improved behavior" means any improvement in anything an animal does in response or reaction to a given stimulus or set of conditions. In this specification, "behavior" is used synonymously with "behavioral function."
[0049]
[0053] Further in this regard, emotional health relates to a sense of well-being and the ability to cope with real life events: people and animals with good emotional health are able to properly manage their thoughts, feelings and behaviors, cope well with real life challenges, are generally in good mental health, and maintain good social interactions.
[0050]
[0054] Signs of declining emotional health include feeling sad or depressed, having confused thinking, exhibiting difficulty concentrating, having excessive fear or worry, or feeling extreme guilt, exhibiting extreme highs and lows in mood, withdrawing from friends (pets) and activities, feeling very tired or with low energy, and having problems sleeping.
[0051]
[0055] The terms "condition" and "disease / disorder" refer to any disease, condition, symptom, or sign. "Prevention" includes reducing the risk, incidence, and / or severity of a condition or disorder. The terms "treatment" and "treating" include both prophylactic or preventative treatment (treatment that prevents and / or delays the onset of the pathological condition or disorder of interest) and curative, therapeutic, or disease-modifying treatment, including, for example, therapeutic measures to cure, delay, reduce symptoms, and / or halt the progression of a diagnosed pathological condition or disorder, as well as treatment of patients at risk of or suspected of having a disease, and patients who are unwell or diagnosed with a disease or medical condition. The terms "treatment" and "treating" do not necessarily mean treating until the subject is cured. The terms "treatment" and "treating" also refer to maintaining and / or promoting the health of an individual who is not afflicted with a disease but who may be susceptible to an unhealthy condition. The terms "treatment" and "treating" are also intended to include the synergism or otherwise enhancement of one or more primary preventative or therapeutic measures. As non-limiting examples, treatment may be performed by a pet owner, a patient, a caregiver, a doctor, a nurse, or another medical professional.
[0052]
[0056] As used herein, a prophylactically or therapeutically "effective amount" is an amount that prevents a deficiency, treats a disease or medical condition in an individual, or more generally, reduces symptoms, manages disease progression, or provides a nutritional, physiological, or medical benefit to an individual. The relative terms "improved," "increased," "enhanced," and the like, refer to the effect of a composition that includes a combination of nutrients disclosed herein (e.g., a combination of spermidine and ellagic acid, or a combination of DHA and curcumin) relative to an otherwise identical composition that does not include the particular combination of ingredients.
[0053]
[0057] The terms "food," "food product," and "food composition" refer to a product or composition intended for ingestion by an individual, such as a companion animal or a human, and providing at least one nutrient to such an individual. The compositions of the present disclosure, including the many embodiments described herein, may comprise, consist of, or consist essentially of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in a dietary regimen.
[0054]
[0058] As used herein, "complete nutrition" refers to a composition that contains sufficient variety and quantity of macronutrients (proteins, lipids, and carbohydrates) and micronutrients to be the sole source of nutrition for the animal to which the composition is administered, such that the individual can receive 100% of the individual's nutritional needs from such a complete nutritional composition.
[0055]
[0059] As used herein, the term "unit dosage form" refers to a physically discrete unit suitable as a dosage unit for human and animal subjects, each unit containing a predetermined amount of a composition disclosed herein, in an amount sufficient to produce the desired effect, together with a pharma- ceutically acceptable diluent, carrier, or vehicle. The specifications for the unit dosage form depend on the particular compound used, the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
[0056]
[0060] Embodiment
[0061] One aspect of the present disclosure is a composition comprising a combination of nutrients, such as a combination of spermidine and ellagic acid, or a combination of docosahexaenoic acid (DHA) and curcumin, in an amount effective to support or enhance cognitive and emotional health (e.g., emotional control of thoughts, feelings, and behaviors) in a mammal.For example, in some embodiments, a unit dosage form comprises an amount of a combination of nutrients, such as a combination of spermidine and ellagic acid, or a combination of docosahexaenoic acid (DHA) and curcumin, in an amount effective to support or enhance cognitive and emotional health in a mammal.
[0057]
[0062] Another aspect of the present disclosure is a method for supporting or enhancing cognitive and emotional health (e.g., enhancing emotional control of thoughts, feelings, and behaviors) in a mammal (e.g., a mammal in need of enhanced cognitive and emotional health), such as an elderly human or companion animal, comprising the steps of (1) identifying an elderly mammal having or at risk for decline in cognitive function and / or emotional health, and (2) administering to the mammal an effective amount of a nutrient combination, such as a combination of spermidine and ellagic acid, or a combination of docosahexaenoic acid (DHA) and curcumin.
[0058]
[0063] Preferably, the method is carried out without calorie restriction.For example, the composition can be administered to a mammal at least once a week, preferably for a period of at least one week, preferably at least one month, and the daily calorie intake during the administration period is substantially the same as the calorie intake of the previous week, preferably the calorie intake of the previous month.
[0059]
[0064] Wheat germ is rich in spermidine. Thus, some embodiments of the present composition include wheat germ and / or concentrated wheat germ extract, which comprises at least a portion of the spermidine in the composition.
[0060]
[0065] Ellagic acid is a phenolic acid. Some embodiments of the composition include pomegranate and / or concentrated pomegranate extract that comprises at least a portion of the ellagic acid in the composition.
[0061]
[0066] Docosahexaenoic acid (DHA) is C22:6n-3. At least a portion of the DHA in the composition may be in free form (as fatty acid or its physiologically acceptable salt) or may be included in the structure of a fatty acid derivative. In some embodiments, the composition comprises a triglyceride comprising at least a portion of DHA. DHA is present in natural sources, such as, for example, eggs, algae, or fish oil.
[0062]
[0067] Curcumin is the polyphenol 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione.
[0063]
[0068] Non-limiting examples of concentrations and / or daily doses of these compounds are provided below.
[0064]
[0069] For curcumin administered to pets, 0.25 mg to 250 mg of curcumin per kg of animal body weight per day is suitable in various embodiments of the methods and compositions disclosed herein. In one aspect, 0.5 mg to about 100 mg of curcumin per kg of animal body weight per day can be administered. Curcumin is preferably present in an amount of 0.00025% to 2% of the food, preferably 0.0005% to 1% of the food.
[0065]
[0070] For curcumin administered to humans, curcumin may be present in an amount of about 0.01 mg to about 2.0 g per serving, preferably about 0.1 mg to about 2.0 g per serving, and even more preferably about 10.0 mg to about 1.0 g per serving.
[0066]
[0071] For humans, particularly preferred phenols are rosmarinic acid, ellagic acid, and chlorogenic acid, or any possible combination or mixture thereof. Each of the phenols, or the sum of these combinations of phenols (or in the form of an extract), can be present in the composition, or in a composition reconstituted from a powder or concentrated form, at a concentration of 0.1% to 1%, 0.15% to 0.8%, 0.15% to 0.7%, 0.15% to 0.6%, 0.15% to 0.5%, 0.2% to 0.4%, or can be present in the composition at a concentration of about 0.3%.
[0067]
[0072] For ellagic acid administered to pets, the preferred dosage in various embodiments of the methods and compositions disclosed herein is 0.1 mg to 1000 mg per kg of animal body weight per day. In one aspect, 1 mg to about 500 mg of ellagic acid per kg of animal body weight per day can be administered. In food, ellagic acid is preferably present at 0.1 mg / kg to 10,000 mg / kg of food, more preferably 10 mg / kg to 1000 mg / kg of food, and most preferably 100 mg / kg to 750 mg / kg of food.
[0068]
[0073] Non-limiting but particularly preferred doses of ellagic acid for humans include a daily dose of 50 mg to 200 mg, and 0.83 mg to 3.33 mg per kg of subject body weight. Non-limiting but particularly preferred doses of ellagic acid for dogs include a daily dose of 15 mg to 60 mg (e.g., for a 10 kg dog), and 1.5 mg to 6 mg per kg of dog body weight. Examples of ellagic acid sources include 2 g to 8 g of raw chestnuts and 87 mL to 350 mL of pomegranate juice.
[0069]
[0074] For DHA administered to pets, a suitable dosage in various embodiments of the methods and compositions disclosed herein is between 1 mg and 1000 mg of DHA per kg of animal weight per day. In one aspect, between 5 mg and about 750 mg of DHA per kg of animal weight per day can be administered. DHA is preferably present in an amount between 0.005% and 2% of the food, preferably between 0.05% and 2% of the food.
[0070]
[0075] For humans, a preferred embodiment of a daily amount of omega-3 fatty acid (e.g., DHA) is from about 50 mg to about 5 g of omega-3 fatty acid per day, preferably from about 100 mg to about 5 g of omega-3 fatty acid per day, more preferably from about 250 mg to about 2.5 g of omega-3 fatty acid per day, and most preferably from about 0.5 g to about 1.5 g of omega-3 fatty acid per day.
[0071]
[0076] For pets, some embodiments of the methods and compositions disclosed herein may include administering a daily dose of an autophagy inducer (e.g., spermidine) in a weight range of 0.05 mg to 1 g per kg of body weight, preferably 1 mg to 200 mg per kg of body weight, more preferably 5 mg to 150 mg per kg of body weight, even more preferably 10 mg to 120 mg per kg of body weight, and most preferably 40 mg to 80 mg per kg of body weight. Typically, 50 pg to 10 g of an autophagy inducer, preferably a spermidine compound, per daily dose may be administered in one or multiple divided doses.
[0072]
[0077] For spermidine administered to humans, the preferred dosage in various embodiments of the methods and compositions disclosed herein is 0.09 mg to 50 mg per kg of animal body weight per day. In one aspect, 0.1 mg to about 25 mg of spermidine per kg of animal body weight per day can be administered. In food, spermidine is preferably present at 0.1 mg / kg to 10.00 mg / kg of food, more preferably 10 mg / kg to 500 mg / kg of food, and most preferably 25 mg / kg to 250 mg / kg of food.
[0073]
[0078] The composition can be formulated for consumption by any mammal. In some embodiments, the mammal is other than a human, and in certain embodiments, the mammal is a companion animal. An exemplary embodiment features a composition formulated for consumption by a pet, such as a companion animal, for example, a dog or a cat. In one embodiment, the mammal is a human. The composition administered to the mammal can be a pet food, a dietary supplement, or a food product formulated for human consumption.
[0074]
[0079] The composition can be formulated for administration to healthy elderly mammals.In certain embodiments, the mammal has a phenotype associated with age-related cognitive impairment.Such phenotypes can include one or more of the following, compared with control animals that do not have the phenotype: reduced recall ability, short-term memory impairment, reduced learning speed, reduced learning ability, reduced problem-solving ability, reduced attention span, reduced motor skills, increased confusion, or dementia.
[0075]
[0080] The composition can be administered periodically, in some embodiments at least once a day.In certain embodiments, the composition is administered as part of a daily dietary regimen for a period of time that spans at least about one week, or at least about one month, or at least about three months to at least about one year or longer of the life of a mammal.The effective dose for treatment can be determined by those skilled in the art and may vary depending on a number of factors known to those skilled in the art, such as the severity of the condition and the weight and general condition of the individual.
[0076]
[0081] The composition is preferably administered to the individual at least 2 days per week, more preferably at least 3 days per week, most preferably 7 days per week; at least 1 week, at least 1 month, at least 2 months, at least 3 months, at least 6 months, or even longer. In some embodiments, the composition is administered to the individual continuously for several days, for example, at least until a therapeutic effect is achieved. In some embodiments, the composition can be administered to the individual daily for at least 30, 60, or 90 consecutive days.
[0077]
[0082] The above dosing examples do not require uninterrupted daily administration. Rather, there may be several short interruptions in administration, such as a 2-4 day break during the administration period. The ideal duration of administration of the composition can be determined by one of skill in the art.
[0078]
[0083] The term "long-term administration" refers to a period of repeated administration or intake that exceeds one month. In certain embodiments, periods of more than 2, 3, or 4 months are preferred. Longer periods are also preferred, including more than 5, 6, 7, 8, 9, or 10 months. Periods of more than 11 months or one year are also preferred. Long-term use, extending for periods of one, two, or three years or more, is included in the present disclosure. For certain elderly animals, the animal will continue regular intake for the remainder of its life. Such intake may also be referred to as "long-term" intake.
[0079]
[0084] In a preferred embodiment, the composition is administered orally or enterally (e.g., tube-fed) to an individual. For example, the composition can be administered to an individual as a drink, capsule, tablet, powder, or suspension.
[0080]
[0085] The composition may be any type of composition suitable for human and / or animal consumption. For example, the composition may be selected from the group consisting of food compositions, dietary supplements, nutritional compositions, nutraceuticals, powdered nutritional formulations that are reconstituted with water or milk before ingestion, food additives, medicines, beverages and drinks. In one embodiment, the composition is an oral nutritional supplement (ONS), a complete nutritional formula, a medicine, a drug or a food product. In a preferred embodiment, the composition is administered to an individual as a drink. The composition may be stored in a sachet as a powder and then suspended in a liquid such as water for use.
[0081]
[0086] In some cases where oral or enteral administration is not possible or advisable, the compositions may also be administered parenterally.
[0082]
[0087] In some embodiments, the compositions are administered to an individual in a single dosage form, i.e., all compounds are present in one product given to the individual in combination with a meal. In other embodiments, the compositions are co-administered in separate dosage forms, e.g., at least one component is co-administered separately from one or more of the other components of the composition.
[0083]
[0088] In various embodiments, the pet food or pet treat composition comprises about 15% to about 50% crude protein. The crude protein material may include vegetable proteins such as soybean meal, soy protein concentrate, corn gluten meal, wheat gluten, cottonseed, and peanut meal, or animal proteins such as casein, albumin, and meat proteins. Examples of meat proteins useful herein include pork, lamb, horse, poultry, fish, and mixtures thereof.
[0084]
[0089] The composition may further comprise about 5% to about 40% fat. The composition may further comprise a carbohydrate source. The composition may comprise about 15% to about 60% carbohydrate. Examples of such carbohydrates include grains or cereals such as rice, corn, milo, sorghum, alfalfa, barley, soybean, canola, oats, wheat, and mixtures thereof. The composition may also optionally include other ingredients such as dried whey and other dairy by-products.
[0085]
[0090] In some embodiments, the ash content of the composition ranges from less than 1% to about 15%, preferably from about 5% to about 10%.
[0086]
[0091] The moisture content may vary depending on the nature of the composition. In a preferred embodiment, the composition may be a complete and nutritionally balanced pet food. In this embodiment, the pet food may be a "wet food", a "dry food", or a food with an intermediate moisture content. "Wet food" refers to pet food that is typically sold in cans or foil bags and typically has a moisture content ranging from about 70% to about 90%. "Dry food" refers to pet food that is of a similar composition to wet food, but contains a limited moisture content, typically ranging from about 5% to about 15% or 20%, and thus is provided, for example, as a small biscuit-like kibble. In one currently preferred embodiment, the composition has a moisture content of about 5% to about 20%. Dry food products include a variety of foods with various moisture contents that are relatively shelf-stable and resistant to microbial or fungal deterioration or contamination. Dry food compositions are also preferred, which are extruded food products such as pet foods, or snack foods for humans or companion animals.
[0087]
[0092] The composition may also include one or more fiber sources. The term "fiber" includes all sources of "bulk" in foods, whether digestible or resistant, soluble or insoluble, fermentable or non-fermentable. The preferred fiber may be derived from plants, such as marine plants, but fiber sources of microbial origin may also be used. As known to those skilled in the art, a variety of soluble or insoluble fibers may be used. The fiber source may be beet pulp (from sugar beet), gum arabic, gum talha, psyllium, rice bran, carob gum, citrus pulp, fructooligosaccharides, pectin, short chain oligofructose, mannan oligofructose, soybean fiber, arabinogalactan, galactooligosaccharides, arabinoxylan, or mixtures thereof.
[0088]
[0093] Alternatively, the fiber source may be fermentable fiber. Fermentable fiber has previously been reported to be beneficial to the immune system of companion animals. Fermentable fiber or other compositions known to those skilled in the art that provide prebiotics to enhance the proliferation of probiotics in the intestine can also be incorporated into the composition to help enhance the effect provided by the present disclosure on the immune system of animals.
[0089]
[0094] In other embodiments, the composition further comprises a prebiotic, a probiotic, or a combination thereof. Probiotics are live microorganisms that, when ingested, have beneficial effects in the prevention and treatment of certain medical conditions. Probiotics are believed to exert their biological effects through a phenomenon known as colonization inhibition. Probiotics promote the process by which the resident anaerobic flora limits the concentration of potentially harmful (mainly aerobic) bacteria in the gastrointestinal tract. Other mechanisms of action, such as the provision of enzymes or the influence of enzyme activity in the gastrointestinal tract, may also constitute part of other functions involved with probiotics.
[0090]
[0095] Prebiotics are non-digestible food ingredients that selectively stimulate bacterial growth and / or activity in the colon, thereby beneficially affecting the health of the host. Prebiotics include fructooligosaccharides (FOS), xylooligosaccharides (XOS), galactooligosaccharides (GOS), and mannooligosaccharides (typically for non-human foods such as pet food). The prebiotic fructooligosaccharides (FOS) are naturally found in many foods, such as wheat, onions, bananas, honey, garlic, and leeks. FOS can also be isolated from chicory root or enzymatically synthesized from sucrose. FOS fermentation in the colon results in a number of physiological effects, including increased numbers of bifidobacteria in the colon, increased calcium absorption, increased fecal weight, decreased gastrointestinal transit time, and possibly reduced blood lipid levels. Increased bifidobacteria are hypothesized to benefit human health by producing compounds to inhibit potential pathogens, lowering blood ammonia levels, and producing vitamins and digestive enzymes.
[0091]
[0096] Probiotic bacteria such as Lactobacilli or Bifidobacteria are believed to positively affect immune responses by improving the balance of the gut microbiota leading to enhanced antibody production and phagocytic (engulfing or killing) activity of white blood cells. Bifidobacterium lactis may be an effective probiotic dietary supplement for enhancing some aspects of cell-mediated immunity in older adults. Probiotics may be useful as dietary supplements to enhance systemic cell-mediated immune responses and boost innate immunity in otherwise healthy adults. Probiotics include many types of bacteria, but are generally selected from four genera: Lactobacillus acidophilus, Bifidobacteria, Lactococcus, and Pediococcus. Beneficial species include Enterococcus and Saccharomyces species.
[0092]
[0097] The amount of probiotics and prebiotics to be administered to an animal is determined by a person skilled in the art based on the type and nature of the prebiotics and probiotics and the type and nature of the animal, such as age, weight, general health, sex, degree of microbial depletion, presence of harmful bacteria, and diet of the animal. In general, probiotics are administered to animals in a viable amount of about 1 to about 20 billion colony forming units (CFU) per day, preferably about 5 to about 10 billion CFU per day, for healthy maintenance of the intestinal microflora.
[0093]
[0098] Generally, prebiotics are administered in amounts sufficient to actively stimulate healthy flora in the gut and allow these "good" bacteria to proliferate, with typical amounts being about 1 gram to about 10 grams per serving, or about 5% to about 40% of the recommended daily amount of dietary fiber for animals.
[0094]
[0099] The probiotics and prebiotics can be part of the composition by any suitable means. Generally, the agent is mixed with the composition or applied to the surface of the composition, for example by sprinkling or spraying. If the agent is part of a kit, the agent may be mixed with other materials or may be in a package for the agent.
[0095]
[0100] In a preferred embodiment, the food composition comprises a macronutrient composition appropriate for the type of food for which it is designed. In one embodiment, the food composition has about 20-32% protein, about 30-50% carbohydrate, about 5-20% fat, and about 15%-25% moisture. In another embodiment, the food composition is a pet food composition, such as a premium pet food composition or a super premium pet food composition. In one embodiment, the pet food can be formulated for dogs and has a protein content of about 20-30%, preferably about 24-28%, more preferably about 25-27%. In one embodiment, the protein content of the dog food composition is about 26% by weight. In another embodiment, the formulation is for cats and has a protein content of about 35-45%, preferably about 37-42%, more preferably about 39-41%. In one embodiment, the protein content of the cat food composition is about 40%. In a preferred embodiment, the composition is a food product comprising about 15% to about 50% protein, about 5% to about 40% fat, about 5% to about 10% ash, and has a moisture content of about 5% to about 20%.
[0096]
[0101] In some embodiments, the food composition can be a wet food, such as a canned food, frozen food, or fresh food product. In some embodiments, the food composition is shelf stable. In other embodiments, the food composition must be refrigerated. In other embodiments, the food composition is an intermediate moisture product or a dry food product as described above.
[0097]
[0102] In some embodiments, the composition is administered to the animal in combination with one or more cognitive drugs in an amount effective to enhance cognitive and related functions as defined herein. In a preferred embodiment, the composition is administered to the animal daily, preferably in a single dose.
[0098]
[0103] In certain embodiments, animal is a healthy aged animal.In other embodiments, animal has a phenotype associated with age-related cognitive impairment.For example, when compared with control animals that do not have this phenotype, animal can have phenotypes that include one or more of the following: reduced recall ability, short-term memory impairment, slow learning speed, reduced learning ability, reduced problem-solving ability, reduced attention span, reduced motor skills, increased confusion, or dementia (Alzheimer's type in humans or the corresponding type in other animals).
[0099]
[0104] In some embodiments, the composition comprises a combination of nutrients, such as a combination of spermidine and ellagic acid, or a combination of docosahexaenoic acid (DHA) and curcumin, in an amount effective to improve one or more social behaviors. In a preferred embodiment, the animal is a companion animal.
[0100]
[0105] In some embodiments, the method provides for (a) reducing or preventing a decline in social interaction in an animal (e.g., to ensure that an older animal remains engaged in playtime, participates in group activities, interacts with caregivers, etc.); (b) reducing or preventing age-related behavioral changes in an animal (e.g., one or more of: amnesia; disorientation; decline in social interaction; changes in sleep and wakefulness habits, particularly increased nocturnal activity; impaired "discipline" resulting in changes in urination and defecation location and pattern; confusion; frustration; changes in temperament, such as agitation and aggression; pacing; and wandering (such changes have been observed in humans and other animals in response to cognitive decline)); (c) increasing the trainability of an animal, e.g., enabling an animal to learn a task or obey verbal, signal, or other commands more quickly than if training were performed without the use of the composition; (d) maintaining optimal brain function in an animal to, for example, mitigate the decline in mental function in older dogs. (e) promoting learning and memory in animals, e.g., helping older animals remember facts and understand instructions; (f) reducing memory impairment in animals; (g) reducing brain aging in animals; (h) preventing or treating stroke in animals, e.g., by reducing damage caused by stroke, where stroke is correlated with certain aspects of enhanced cognitive function, e.g., reduced memory impairment; (i) preventing or treating dementia in animals, e.g., Alzheimer's Disease (AD) in humans, Canine Cognitive Dysfunction Syndrome (CCDS) in dogs, or similar diseases in other animals, e.g., by reducing the effects of damage resulting from causes of dementia, such as amyloid deposits or reduced arterial function; (j) maintaining mental clarity and alertness in animals; (k) promoting health and wellness in animals; and (l) extending the prime years of animals or animals.
[0101]
[0106] Thus, in view of the above disclosure, one embodiment is a method of enhancing cognitive function and emotional well-being in a mammal, comprising administering to the mammal a composition comprising at least one of: (a) a combination of spermidine and ellagic acid; or (b) a combination of docosahexaenoic acid (DHA) and curcumin.
[0102]
[0107] In some embodiments, the mammal is a senior or geriatric human or a senior or geriatric companion animal, preferably a geriatric dog.
[0103]
[0108] In some embodiments, the mammal has a phenotype associated with age-related cognitive impairment, preferably comprising one or more of: impaired recall, impaired short-term memory, slower learning rate, slower learning ability, slower problem-solving ability, reduced attention span, impaired motor skills, increased confusion, or dementia, relative to a control mammal not having the phenotype.
[0104]
[0109] In some embodiments, enhancing emotional health comprises reducing at least one of anxiety, stress, aggression, hopelessness, lack of concentration, or irritability, and / or improving at least one of mood or social behavior.
[0105]
[0110] In some embodiments, the administering step uses at least one route selected from the group of oral administration, enteral administration, parenteral administration, and intravenous injection.
[0106]
[0111] In some embodiments, the composition has a form selected from the group consisting of a pet food, a dietary supplement, and a food formulated for human consumption.
[0107]
[0112] Another embodiment is a unit dosage form of a composition comprising at least one of (a) a combination of spermidine and ellagic acid, or (b) a combination of docosahexaenoic acid (DHA) and curcumin, in an amount effective to enhance cognitive function and emotional health in a mammal to which the composition is administered. In some embodiments, the mammal is a senior or geriatric human, or a senior or geriatric companion animal, preferably a geriatric dog.
[0108]
[0113] Yet another embodiment is a method of preparing a composition for administration to a mammal, comprising adding at least one of (a) a combination of spermidine and ellagic acid, or (b) a combination of docosahexaenoic acid (DHA) and curcumin to at least one other ingredient to form a composition. In some embodiments, the composition is formulated for administration by at least one route selected from the group of oral administration, enteral administration, parenteral administration, and intravenous injection. In some embodiments, the at least one other ingredient is selected from the group consisting of proteins, carbohydrates, lipids, vitamins, minerals, probiotics, prebiotics, and mixtures thereof. In some embodiments, the mammal is a senior or geriatric human, or a senior or geriatric companion animal, preferably a geriatric dog.
[0109]
[0114] Another embodiment is a method comprising administering a composition comprising at least one of (a) a combination of spermidine and ellagic acid, or (b) a combination of docosahexaenoic acid (DHA) and curcumin, wherein the composition is administered to the mammal in an amount effective to enhance cognitive function and emotional health in the mammal.In some embodiments, the composition is administered by at least one route selected from the group of oral administration, enteral administration, parenteral administration, and intravenous injection.In some embodiments, the mammal is an elderly or aged human, or an elderly or aged companion animal, preferably an elderly dog. EXAMPLES
[0110]
[0116] The following non-limiting examples present clinical data that develop and support the inventive concepts disclosed herein.
[0111]
[0117] Selected candidate nutrients were tested, specifically spermidine (a polyamine) which may be provided by whole food sources such as wheat germ, soy, cheese, and poultry; resveratrol (a stilbenoid) which may be provided by whole food sources such as Japanese knotweed (polygonum cuspidatum) extract; ellagic acid (a dilactone) which may be provided by whole food sources such as pomegranate extract and pomace; curcumin (a curcuminoid) which may be provided by whole food sources such as curcuma longa; EPA and DHA (omega-3 fatty acids) which may be provided by whole food sources such as fish oil; L-theanine (an amino acid analogue) which may be provided by whole food sources such as tea extract; beta-hydroxybutyric acid (BHB-ketone); thymol; and isoflavones which may be provided by whole food sources such as soy.
[0112]
[0118] The results show that the combination of DHA and curcumin had no difference in autophagy-related genes (Figures 1A and 1B), but had a significant synergistic effect on lysosomal genes (Figures 2A and 2B).The results also show that the combination of spermidine and ellagic acid had no difference in autophagy-related genes (Figures 3A and 3B), but had a significant synergistic effect on lysosomal genes (Figures 4A and 4B).
[0113]
[0119] These results are reasonable when compared with the literature. For example, Fu X. et al. (Experimental Neurology 2021) found that molecules such as PF11, which acts through TFEB, increase Lamp1 and Ctsd mRNA as well as the two blends mentioned above (DHA and curcumin, and spermidine and ellagic acid), and are neuroprotective. As another example, Huang et al. (CNS, Neuroscience and Therapeutics 2018) found that exercise activates lysosomal function in the brain more efficiently than trehalose via the SIRT1-TFEB pathway.
[0114]
[0120] The scientific evidence is summarized below:
[0115]
[0121] Autophagy flux is associated with synaptic function and psychiatric disorders (for review, see Tomoda T. et al, Biological Psychiatry 2019)
[0116]
[0122] Autophagy flux and lysosomal activity are key regulators of balanced excitatory and inhibitory neurotransmission in the brain (see Sumitomo A. et al., Human Molecular Genetics 2018; Kuijpers M. et al., Neuron 2020; Hui KK. et al., Science Advances 2019; Lakhani R. et al., EMBO Molecular Medicine 2014).
[0117]
[0123] Autophagy flux and lysosomal activity are important mediators of mood stabilizer and stress response (Shu X. et al., Cell Death and Disease 2019; Gulbins A. et al., Molecular Psychiatry 2018; Gassen NC et al., Plos Medicine 2014; Limanaqi F. et al., Frontiers in Psychatry 2020; Zhou et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry 2015; Wang S. et al., Neuroscience Letters 2021).
[0118]
[0124] Autophagy flux and lysosomal activity support neurogenesis and brain and mental health through multiple mechanisms, including those mentioned above (Leeman DS. et al., Science 2018; Fleming A. et al., Trends in Neuroscience 2020).
[0119]
[0125] It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. Accordingly, such changes and modifications are intended to be encompassed by the appended claims.
Claims
1. 1. A method for enhancing cognitive function and emotional health in a mammal, comprising administering to the mammal a composition comprising at least one of: (a) a combination of spermidine and ellagic acid; or (b) a combination of docosahexaenoic acid (DHA) and curcumin.
2. 2. The method of claim 1, wherein the mammal is an elderly or geriatric human or an elderly or geriatric companion animal, preferably an elderly dog.
3. 2. The method of claim 1, wherein the mammal has a phenotype associated with age-related cognitive impairment, preferably the phenotype comprises one or more of: impaired recall ability, impaired short-term memory, slower learning rate, slower learning ability, slower problem-solving ability, reduced attention span, slower motor skills, increased confusion, or dementia, compared to a control mammal not having the phenotype.
4. 10. The method of claim 1, wherein the enhancing emotional health comprises reducing at least one of anxiety, stress, aggression, hopelessness, lack of concentration, or irritability, and / or improving at least one of mood or social behavior.
5. 10. The method of claim 1, wherein the administering step uses at least one route selected from the group of oral administration, enteral administration, parenteral administration, and intravenous injection.
6. 10. The method of claim 1, wherein the composition has a form selected from the group consisting of a pet food, a dietary supplement, and a food product formulated for human consumption.
7. A unit dosage form of a composition comprising at least one of (a) a combination of spermidine and ellagic acid, or (b) a combination of docosahexaenoic acid (DHA) and curcumin, in an amount effective to enhance cognitive function and emotional health in a mammal to which the composition is administered.
8. 8. The unit dosage form of claim 7, wherein the mammal is a senior or geriatric human or a senior or geriatric companion animal, preferably a geriatric dog.
9. 1. A method of producing a composition for administration to a mammal, the method comprising adding at least one of (a) a combination of spermidine and ellagic acid, or (b) a combination of docosahexaenoic acid (DHA) and curcumin to at least one other raw material to form the composition.
10. 10. The method of claim 9, wherein the composition is formulated for administration by at least one route selected from the group of oral administration, enteral administration, parenteral administration, and intravenous injection.
11. 10. The method of claim 9, wherein the at least one other ingredient is selected from the group consisting of proteins, carbohydrates, lipids, vitamins, minerals, probiotics, prebiotics, and mixtures thereof.
12. 10. The method of claim 9, wherein the mammal is an elderly or geriatric human or an elderly or geriatric companion animal, preferably an elderly dog.
13. 1. A method comprising the step of administering a composition comprising at least one of (a) a combination of spermidine and ellagic acid, or (b) a combination of docosahexaenoic acid (DHA) and curcumin, wherein the composition is administered to the mammal in an amount effective to enhance cognitive function and emotional health in the mammal.
14. 14. The method of claim 13, wherein the composition is administered by at least one route selected from the group of oral administration, enteral administration, parenteral administration, and intravenous injection.
15. 14. The method of claim 13, wherein the mammal is a senior or geriatric human or a senior or geriatric companion animal, preferably a geriatric dog.
Citation Information
Patent Citations
Enhancement of autophagy or extension of lifespan by administration of urolithin or its precursors.
JP2015523362A
